A nutritional approach could be a promising strategy to prevent or slow the progression of neurodegenerative diseases such as Parkinson's and Alzheimer's disease, since there is no effective therapy for these diseases so far. The beneficial effects of omega-3 fatty acids are now well established by a plethora of studies through their involvement in multiple biochemical functions, including synthesis of antinflammatory mediators, cell membrane fluidity, intracellular signalling and gene expression. This systematic review will consider epidemiological studies and clinical trials that assessed the impact of supplementation or dietary intake of omega-3 polyunsaturated fatty acids on neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. Indeed, treatment with omega-3 fatty acids, being safe and well tolerated, represent a valuable and biologically plausible tool in the management of neurodegenerative diseases in their early stages.
Introduction
Several cerebral functions are determined by some nutrients, such as omega-3 polyunsaturated fatty acids (PUFAs), which are key membrane components involved in the proper neuronal functions through a range of potential mechanisms including increase of new synapse formation [1] , effects on synaptic function, integrity and neurochemistry, and synaptic plasticity [2] [3] [4] [5] . On the whole, this contributes to neuroplasticity, which it is associated with the enhancement of cognitive activity [6] .
There is accumulating scientific evidence on the possible efficacy of PUFAs supplementation in neurodegenerative disorders [7, 8] , such as Parkinson's (PD) and Alzheimer's disease (AD) [9] [10] [11] [12] [13] . Although dietary recommendations are far from being a treatment for PD or AD, they may be able to alleviate some of the symptoms or slow the cognitive and physical decline. The present study systematically reviews the effects of omega-3 polyunsaturated fatty acids' supplementation on cognitive function in patients with Parkinson's or Alzheimer's disease. The main classes of PUFAs belong to the omega-3 one, which comprises -linolenic acid (ALA, 18:3 -3), eicosapentaenoic acid (EPA, 20:5 -3) and docosahexaenoic acid (DHA, 22:6 -3) and to the omega-6 one, which comprises linoleic acid (LA, 18:2 -6) and arachidonic acid (ARA, 20:4 -6) [14] . DHA and ARA are the most important PUFAs in the brain [15] ; in particular, DHA constitutes over 90% of the -3 PUFAs and 
Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra, pars compacta. A pathological hallmark of the disease is also the presence of Lewy bodies, which are intracellular inclusions enriched in the protein -synuclein. The common symptoms include tremor, rigidity, bradykinesia and postural insecurity, with dementia and depression observed in the advanced stages of the disease [30] . In a significant number of cases, depression appeared before the expression of Parkinson's classic symptoms, even previous to any evidence of motor impairment. Moreover, a recent study observed that people diagnosed with depression are three fold more inclined to develop PD [45] . One-third of PD patients suffer depression that may lead to worse health outcomes and to a decreased quality of life. Anxiety, apathy and anhedonia further complicate PD outcomes [30] . Although the aetiology is currently unknown, there are a number of putative risk factors (e.g. exposure to environmental toxins) [46] and the pathogenic mechanisms include mitochondrial dysfunction, neuroinflammation and oxidative stress [47] . However, numerous studies support that a diet rich in PUFAs or supplementation with food products containing EPA and DHA could alleviate some of the patients' symptoms. The main scales used to evaluate PD symptoms are summarized in Table 2 . 
Main scales Description
Activities of Daily Living ADCS-ADL; ADCS-IADL It measures the functional ability to perform activities of daily life. ADL assess basic living skills such as bathing and eating, whereas IADL measure more complex tasks such as using the telephone or preparing meals. A higher ADL or IADL score indicates a worsening functionality.
Is a sensitive and reliable method for the assessment of cognitive function in dementias. It consists of a psychometric scale of 11 items, and scores range from 0 (no impairment) to 70 (very severe impairment). Beck Depression Inventory (BDI)
It is a 21-question multiple-choice self-report inventory, one of the most widely used psychometric tests for measuring the severity of depression.
Brief Assessment Schedule Depression Cards (BASDEC)
It is a brief test for screening depression, requiring minimal training to administer.
Bristol's Activities of Daily Living Scale (BADLS)
It is specifically designed for individuals with mild dementia living in the community for completion by caregivers.
Clinical Dementia Rating (CDR)
It is a global measure that assesses memory, orientation, judgment, and other features. Is based on caregiver interview. Classifies dementia into questionable, mild, moderate, and severe.
Clinical Global Impression Scale (CGI)
It measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders.
Clinician Interview-Based Impression of Change, plus carer interview (CIBIC-Plus)
It is a global measure capable of detecting changes in cognition, functionality, and behavior, thus assessing dementia's severity and progression. Requires separate interviews with patients and caregivers.
Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV)
Is the handbook used by health care professionals in the United States and much of the world as the authoritative guide to the diagnosis of mental disorders.
Hamilton Depression Rating Scale (HDRS)
Is the most widely used clinician-administered depression assessment scale. The original version contains 17 items pertaining to symptoms of depression experienced over the past week.
Hoehn and Yahr scale
It is a commonly used system for describing how the symptoms of PD progress.
Hopkins Verbal Learning TestRevised (HVLT-R)
It is a brief verbal learning and memory test ideal in situations calling for repeated neuropsychological examinations. [51]
249 PD Japan Self-administered diet history questionnaire 6 years Consumption of omega-3 PUFA, ALA, EPA, DHA were not associated with PD.
[52]
In The Rotterdam Study the intakes of total fats, MUFAs and PUFAs were significantly associated with a lower risk of PD, by means of energy-adjusted intake of fat and fatty acids [50] . The Health Professionals Follow-Up Study (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) and the Nurses' Health Study (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) , including 131.368 men and women, evaluated the associations between dietary patterns and risk of PD. The main components analysis identified two dietary patterns: prudent and Western. The prudent dietary pattern, characterized by high intakes of fruit, vegetables and fish, was inversely associated with PD risk, but the Western pattern was not [51] . However a case-control study, which examined the relationship between dietary intake of individual fatty acids and the risk of PD in Japan, including 249 cases within 6 years of onset of PD, demonstrated that intake of omega-3 polyunsaturated fatty acids were not associated with PD. Higher consumption of ARA and cholesterol, instead, may be related to an increased risk of PD [52] . In summary we can conclude that prospective observational studies showed an association between a diet rich in polyunsaturated omega-3 fatty acids with a lower risk of PD.
patient adherence to diet therapy, duration of dietary treatment, control of clinical parameters and evaluation of these same parameters. When the pathology occurs, already 70% of neurons are compromised; thus thinking that only a dietary treatment can restore brain functions is really an utopia. However, dietary treatments with omega-3 fatty acids may have advantages in reducing inflammation and, consequently, depressive symptoms. Indeed, treatment for 6 months with 800 mg/day DHA and 290 mg/day EPA from fish oil, demonstrated, in the DHA treated patients, a reduction of 50% in the Hamilton Rating Scale for Depression (HDRS) total score if compared with the placebo group which took corn oil. DHA integration reduced the depressive symptoms [53] . However, treatment had no statistically significant effect on rate of change on either Unified Parkinson's Disease Rating Scale (UPDRS) or Hoehn-Yahr Scale score [53] (Table 4) . Another double-blind, placebo-controlled study analyzed the effect of fish oil supplementation in parkinsonian patients with depression measured using Montgomery-Asberg Rating Scale (MADRS), the Clinical Global Impressions Scale (CGI) and Beck Depression Inventory (BDI) [45] . After 3 months, the supplementation of 4 capsules of omega-3 from fish oil (each capsule containing 180 mg EPA, 120 mg DHA and tocopherol) showed a significant decrease in MADRS and CGI-Depression scores while there was no difference among treated and control groups in BDI [45] . Moreover, Parkinson's symptoms, measured by Hoehn and Yahr scale, did not show significant variation during the 3 months of supplementation in all groups observed [45] . A randomized double-blind placebo-controlled clinical trial, conducted in 60 patients with PD, receiving either 1000 mg omega-3 fatty acids from flaxseed oil plus 400 IU vitamin E supplements or placebo for 3 months, showed that the dietetic supplementation in people with PD improved UPDRS compared with the placebo [54] . The published papers give an important indication on the use of omega-3 supplements especially for depression in PD; however, the number of patients recruited is small and also the type of supplement varies. It is widely demonstrated that the effective dose is 1 g/day of DHA. Animal or algal sources ensure a correct intake of DHA, while plant sources are often ineffective, since only 10% of ALA is metabolised to DHA. Despite this, the supplementation of omega 3 from linseed oil and vitamins E had favorable effects not only on UPDRS but also on high-sensitivity C-reactive protein (hs-CRP), total antioxidant capacity (TAC), glutathione and markers of insulin metabolism [54] . Furthermore, the 3-6 month treatment is a relatively short period considering that we deal with dietary intervention in a pathology where the main symptoms are already evident [45, 53, 54] .
Alzheimer's Disease
Alzheimer's Disease is a neurodegenerative disorder that accounts for the majority of cases of dementia, affecting over 35 million people worldwide. Some of the more usual clinical features include cognitive impairment, memory loss, language disorders, sudden changes of mood and behavior, and disorientation in time and space, hindering the patient's ability to perform normal daily activities. The neurodegenerative process observed in AD is usually present in patients' brain before the appearance of the first symptoms [55] . AD key features are the presence of neurofibrillary tangles and senile plaques and neuronal loss, resulting in cerebral atrophy. Neurofibrillary tangles are composed of abnormal tau protein aggregates. Under normal conditions, tau protein contributes to the cytoskeleton structure by interacting with tubulin in order to stabilise the microtubule network. However, it may suffer different post-transcriptional modifications, such as truncation or hyperphosphorylation. Although the reasons that motivate these modifications remain elusive, there is compelling evidence that this hyperphosphorylated form is prone to aggregate, leading to the formation of neurofibrillary tangles that constitute toxic intracellular accumulations, mainly located in the hippocampus. Moreover, tau protein malfunction produces cytoskeleton destabilisation due to microtubule collapse, prompting synaptic failure that results in a loss of communication, thus contributing to AD-mediated neurodegeneration.
Since mitochondrial transport depends on its interactions with microtubules, this process is hindered upon tau hyperphosphorylation, causing energy deficits in presynaptic areas that may lead to synaptic disruption. Senile plaques consist of extracellular deposits of -amyloid peptide (A), originating from amyloid precursor protein (APP) degradation. Such deposits cause inflammation and neuronal death. APP is a transmembrane protein present in neurons, which can be processed following two different routes: the amyloidogenic and the non-amyloidogenic pathways, both mediated by secretases: -and -secretases take part in the first one, while -and -secretases in the second one ( Figure 2 ) [55] . In the non-amyloidogenic route, APP is sequentially cleaved by -secretase and  -secretase, giving rise to truncated peptides, A17-40/42 ( Figure 2 ). In the amyloidogenic route, on the other hand, the sequential cleavage is carried out by -secretase and -secretase, leading to whole-length A peptides, responsible for the formation of the plaques. Both routes yield an amino-terminal fragment (APPs for the non-amyloidogenic route and APPs for the amyloidogenic route) and a carboxy-terminal one (C83 and C99, respectively). The action of -secretase generates the APP intracellular domain (AICD), which participates in the cellular signalling. Depending on the point where -secretase performs the cut in the amyloidogenic route, the whole-length A peptide would have a different dimension, with A1-40 and A1-42 being the dominant fragments in the brain (Figure 2 ) [55] . It has been shown that DHA increases the non-amyloidogenic processing resulting in an elevated -secreted APP level by an increase in ADAM17 protein levels, caused by upregulated gene expression and decreased protein degradation. Additionally, DHA attenuates amyloidogenic processing affecting both -and -secretase activity by independent mechanisms [56] .
The role of omega-3 polyunsaturated fatty acids in AD: observational studies
The strongest support for a causal association between low fish and/or low DHA intake in AD comes from prospective epidemiological studies conducted in the Netherlands, USA and France. Of the 7 prospective studies that have been published, most show that higher intake of fish or omega-3 PUFA decreases the risk of AD (Table 5 ) [57] . The Rotterdam Study was the first to report that fish intake was inversely related to incident dementia in particular to Alzheimer's disease [58] . The data are confirmed by subsequent studies where the consumption of omega 3 [59] or fatty fish [60] or adherence to a diet rich in fruit, vegetables, fish and oils rich in omega 3 [62, 64] , is associated with a reduction in AD risk. Only a study published by Devore et al. [63] showed that a moderate consumption of fish and omega 3 PUFAs, do not appear to be associated with long-term dementia risk.
The role of omega-3 polyunsaturated fatty acids in AD: randomized, double-blind, placebo-controlled clinical trials
The first randomized clinical trial controlled by placebo (OmegAD Study) that evaluated omega-3 fatty acids' impact in AD was published in 2006 [65] (Table 6 ). The effect of omega-3 supplementation on MMSE and CDR appeared to be influenced by homocysteine plasma levels.
[80]
Freund-Levi et al. [65] assessed omega-3 fatty acids' supplementation in 204 subjects with mild to moderate AD. The treated group received omega-3 fatty acids in the daily dosages of 1720 mg DHA and 600 mg EPA and the placebo group received 4000 mg of corn oil (containing 2400 mg LA) for 6 months, followed by additional 6 months of omega-3 fatty acids' supplementation for both groups. Medication for AD treatment was allowed. As a result, there was no significant statistical difference after a 6 -or 12-month treatment between groups in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). In a subgroup with very mild AD (MMSE>27 and CDR 0.5-1), there was a significant reduction in decline rate between intervention and placebo groups in the first 6 months. In a second paper published in 2008, Freund-Levi et al. [66] , using the same sample from 2006, showed that supplementation with omega-3 in patients with mild to moderate AD did not result in marked effects on neuropsychiatric symptoms except from possible positive effects on depression (assessed by MADRS) in non-APOE4 carriers and agitation symptoms (assessed by Neuropsychiatric Inventory, NPI) in APOE4 carriers. The mechanism of action of omega-3 in the brain in relation to behavior is not fully understood. In rats, it has been shown that an increased intake of both EPA and DHA, whereas a combination of the two omega-3 PUFAs inhibit protein kinase C (PKC) activity after subchronic exposition in cell cultures. Well established mood stabilizers such as lithium and valproic acid are known to inhibit PKC activity. Thus, inhibition of PKC may also represent a potential mode of action of omega-3 in bipolar disorders. Other possible mechanisms could be that omega-3 fatty acids affect neurotransmitter levels and membrane fluidity also by decreasing production of pro inflammatory eicosanoids that might be elevated in depression [66] . Chiu et al. [67] studied 46 subjects with mild to moderate AD or mild cognitive impairment (DSM-IV: MMSE 10-26, CDR-score 1-2). During 6 months, intervention group received 720 mg/die DHA and 1080 mg/die EPA, while placebo group received olive oil. Medication for AD treatment was not allowed. There was no significant statistical difference in MMSE, ADAS-cog and HDRS between the two groups. The negative results of cognitive assessments support the previous studies by Freund-Levi et al. [65, 66] , and all of the studies showed there might be a positive effect of omega-3 fatty acids only in subgroups with mild cognitive deficits. A significant improvement was observed in Clinician Interview-Based Impression of Change, plus carer interview (CIBIC-plus) in the intervention group compared to placebo group. This might be accounted for the cognitive and behavioral components rather than the functional one. It has been suggested that omega-3 fatty acids may have beneficial effects on mood, although this is an unlikely explanation for these findings because of the stringent exclusion of people with significant depression and the lack of association with HDRS score. The relative improvement of general clinical conditions might have resulted from amelioration in other areas of health, such as cardiovascular or immunological systems on which beneficial effects of omega 3 PUFAs have been reported [67] . In a subgroup, participants with mild cognitive impairment (MMSE>27 e CDR 0.5-1) but not with AD, showed a significant additional delay in ADAS-cog decline compared to placebo group. Quinn et al. [68] assessed 402 subjects with mild to moderate AD. The intervention group received DHA 2000 mg/die from seaweed and the placebo group received corn or soy oil for 18 months. Medication for AD treatment was allowed. Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer's disease (no beneficial effect on rate of change on MMSE, ADAS-cog, CDR, ADS-ADL and NPI). Sheltens et al. [69] assessed 225 subjects with mild AD. The intervention group received DHA 1700 mg/die and EPA 600 mg/die from a medical food named Souvenaid and the placebo group received a control drink for 6 months. Significant improvement in the delayed verbal recall task was noted in the supplemented group compared with control. ADAS-cog and other outcome scores (CIBIC-plus, NPI, ADCS-ADL) remained unchanged.
The same authors published a study [70] where the same above-mentioned population was divided into two subgroups: patients with 'low' baseline ADAS-cog scores (<25.0) and patients with 'high' baseline ADAS-cog scores (≥25.0). Repeated measures models were used to determine the relationship between ADAS-cog score and intervention. Baseline ADAS-cog significantly influenced the effect of Souvenaid intervention on ADAScog outcome. A higher intake of the medical food was also associated with greater cognitive benefit. Based on these results, two double-blind, randomized controlled clinical trials were designed. The Souvenir II study examined the effect of longer treatment duration (6 months) with Souvenaid as compared with control product on memory performance in drug-naïve mild AD [81] . Neuropsychological Test Battery (NTB) memory domain increased in active group.
Since the ADAS-cog may be more sensitive to change in moderate AD and since Souvenaid had not been tested in moderate AD patients already taking AD medications, a novel S-Connect study was designed. In this double-blind, parallel, randomized, controlled clinical study, the efficacy and tolerability of Souvenaid was investigated in 527 persons with mild to moderate AD taking stable doses of Souvenaid [72] . Cognitive performance as assessed by ADAS-cog showed decline over time in both control and active study groups, with no significant difference between study groups themselves. Intake of Souvenaid did not slow cognitive decline in persons treated for mild to moderate AD. Faxen-Irving et al., as a part of a previously published study on a DHA rich supplementation to subjects with AD [65] , explored the effects of transthyretin on plasma and CSF. Since plasma transthyretin correlated with MMSE and inversely with ADAS-Cog, these authors suggest a potential mechanism for probable positive effects of omega 3 on cognition. Shinto et al. [74] studied 39 subjects with probable AD in a randomized placebo-controlled pilot with three arms. Two groups received omega 3 fatty acids' supplementation, one only omega-3 fatty acids (DHA 675 mg/die and EPA 975 mg/die), and the other with the addition of alpha lipoic acid (600 mg/die); placebo group received soy oil. The intervention lasted 12 months and medication for AD was allowed. There were no differences in ADAS-cog and ADL between placebo and omega-3 fatty acids or between placebo and omega-3 fatty acids + alpha lipoic acid. In MMSE, the mean alteration between placebo group and intervention group with only omega-3 fatty acids was not significant, whereas the difference between placebo and omega-3 fatty acids + alpha lipoic acid was significant. The mean alteration in IADL (Table 2) was significant between placebo group and omega-3 fatty acids' group and between placebo and omega-3 fatty acids + alpha lipoic acid. In a secondary analysis of the Souvenir II study [75] , results suggest that Souvenaid preserves the organisation of brain networks in patients with mild AD within 6 months, hypothetically counteracting the progressive network disruption over time in AD. These results strengthen the hypothesis that Souvenaid affects synaptic integrity and function. Phillips et al. [76] assessed omega-3 fatty acids' supplementation in 19 subjects with AD. The intervention group received daily omega-3 fatty acids in the dosages of 625 mg DHA and 600 mg EPA and the placebo group received olive oil for 4 months. The daily supplementation was associated with none or only negligible benefits on mood and cognition assessed by MMSE, the Hopkins Verbal Learning Test-Revised (HVLT-R), Brief Assessment Schedule Depression Cards (BASDEC) and Bristol's Activities of Daily Living Scale (BADLS). Data obtained in the OmegAD study [66, 82] were collected to examine the relationship of plasma omega-3 levels to cognitive scores (using ADAS-cog and the MMSE) [83] . The daily supplementation stabilizes the cognitive performance of AD subjects assessed by ADAS-cog and MMSE scores. Also from the OmegAD study a decrease was observed in resolvin D1 (RvD1) and lipoxin A4 (LXA4) production from peripheral blood mononuclear cells of AD patients who did not receive omega-3 supplementation but not in cells of AD subjects under omega-3 intake [78] .
Recent systematic meta-analysis did not show any significant benefits of omega-3 fatty acids supplementation in the treatment of mild to moderate AD, even if the treatment did not raise any substantial safety issues [13] . In fact studies concerning the tolerability, safety and effect size of Souvenaid demonstrated that the use of medical food for up to 12 months was well tolerated, with a favorable safety profile and high adherence of intake [79, 84] . Moreover the efficacy of omega-3 supplementation seems to be influenced by the baseline levels of plasma total homocysteine, suggesting that adequate B vitamin status is required to obtain beneficial effects of omega-3 on cognitive performance in moderate AD [80] .
Materials and Methods
The authors searched PubMed, Web of Science and Scopus articles using a combination of "omega-3 fatty acids,", "Parkinson's Disease, "Alzheimer's Disease", "clinical trials" as keywords. Inclusion criteria consisted in original intervention studies, controlled by placebo, that assessed omega-3 polyunsaturated fatty acids impact on cognitive function in humans with PD or AD, until May 2019, without limitation for the initial date of publication. We searched for interventions using omega-3 polyunsaturated fatty acids as supplementation (in capsules, or in any other form than in food itself) or as increased dietary intake (throughout food sources, such as fish or fish oils). We first applied eligibility criteria in titles' analysis, followed by abstracts' analysis and full texts' reading. Search, selection, and information extraction were performed independently by two reviewers. In order to favor reliability, data were collected independently in a table including number of patients, population characteristics, type and dose of supplementation, exposure period, results and references. The authors prepared references using Zotero as bibliography software.
Conclusions
Neurodegenerative conditions, such as Parkinson's disease and Alzheimer's disease, represent a challenging issue in clinical medicine, and their burden is expected to increase dramatically in the forthcoming decades. At the present time no etiological treatment is routinely available and medical therapy is mainly symptomatic; the adoption of a nutritional approach would be highly recommendable. Omega-3 fatty acids represent an interesting biological potential, in view of their anti-inflammatory and metabolic properties, in the management of these diseases. Indeed, the evidence deriving from prospective observational studies is encouraging, both for Parkinson's and Alzheimer's disease. The adoption of a dietary regimen enriched in omega-3 fatty acids rather consistently associates with a reduced risk of either condition. On the other hand, randomized trials have provided conflicting results, and many of them have failed to document a definite protective effect. This was confirmed by most reviews and meta-analyses performed so far. The inconsistency between observational and randomized studies is not unusual in clinical research, particularly when considering treatment with dietary supplements or integrators. A number of reasons may account for this finding. Firstly, in controlled trials dietary supplementation is usually carried out over a relatively limited time span, compared with the life-long exposure of real-life observational studies. Furthermore, and possibly more importantly, the variations in dietary patterns might reflect the adoption of a healthier lifestyle, in adjunct to the contribution provided by the single nutrient supplementation. This was postulated, for instance, when investigating the protective effects of the Mediterranean diet on cognitive performances. In the present context, intake of higher amounts of foods containing omega-3 fatty acids might associate with a reduced intake of other nutrients, such as meat. Finally, the possibility of different individual responses to the dietary intervention must be considered. As mentioned in this review, the protective effects exerted by omega-3 fatty acids is likely to be modulated by patient-related factors, some of which may have a significant genetic component and may therefore be unmodifiable, and unpredictable with routine clinical and biochemical evaluation. At any rate, treatment with omega-3 fatty acids was generally reported to be safe and well tolerated. In our opinion, they may indeed represent a valuable and biologically plausible tool in the management of neurodegenerative diseases. Of course, supplementation needs to be a part of a global lifestyle intervention, and has to take place in the early stages of the disease, when a benefit may be detected. Hopefully, in a near future the adoption of personalized treatment strategies, aimed to predict individual responses, will help to optimize the effectiveness of such intervention, in order to face the progressive rise of these devastating conditions.
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